By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
5 Bike Brands for Ordinary Use - 2Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- 3The most effective method to Connect Successfully with Teachers in a Web based Setting
- 4Israeli naval intelligence reduces Iranian threat to Strait of Hormuz
- 5Israeli military says it hit dozens of military facilities in Tehran
- The Best Internet based Courses for Expertise Improvement
- Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
- Scientists document a death from a meat allergy tied to certain ticks
- Thousands of Walgreens nasal spray bottles recalled. See which ones.
- Which Film Has the Incomparable Melodic Score?
- Vote In favor of Your Favored Distributed computing Administration
- 25 Most Beautiful Villages in France You Can Actually Visit
- Paraplegic engineer becomes the first wheelchair user to blast into space
- Figure out How to Augment the Advantages of a Web-based Degree
